~~<i id='BF1A13D2EC'><strike id='BF1A13D2EC'><tt id='BF1A13D2EC'><pre id='BF1A13D2EC'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

leisure time

author：knowledge 2025-09-09 19:31:57 - browse：463

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： High breast density mammograms need follow

leisure time

hotspot

focus

explore

knowledge

BENOITDOPPAGNE/BELGAMAG/AFPviaGettyImagesMillionsofAmericanwomenoverage40receiveregularmammogramstos

WSS

Complete sequence of Y chromosome published for first time

FDA sets aggressive timeline for overhauling inspection procedures

AstraZeneca bets AAV gene therapy will still deliver the goods

CVS is on a mission to consolidate health care. Will it work?

What AAP's gender

Mass General, Mayo Clinic look to monetize custom

focus

leisure time

leisure time

Hepatitis C has a cure — but many Americans still lack access to it

Future doctors need a strong humanities education

23andMe had bad news about my health. I wish a person had delivered it

High breast density mammograms need follow

What does generative AI mean for health care? We asked experts

2024 GOP presidential candidates spar over abortion in debate

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

How to make Best Hospitals ratings actually useful for patients

Medicare details structure of new drug price negotiation program

Feds fine Medicare Advantage plans for overcharging members

hotspot

CDC advisory panel says seniors 'may' get RSV vaccine

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

Drug firms test therapies to halt Alzheimer’s before symptoms arise

Radiation, mainstay of cancer treatment, begins a fade

FDA endorses new sterilization method for medical devices

Mass General, Mayo Clinic look to monetize custom

focus

explore

knowledge

knowledge